Periodic Reporting for period 1 - DOWN-AUTONOMY (LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome.)

Overactivity of the DYRK1A protein kinase is involved in cognitive impairments associated with Down Syndrome and Alzheimer’s Disease. Around 150,000 children with Down Syndrome live in Western countries. All of them experience a delay in their learning times from birth, and...